| Literature DB >> 25598708 |
Emma Katengua-Thamahane1, Jeanine L Marnewick2, Olawale R Ajuwon3, Novel N Chegou3, Gergő Szűcs4, Péter Ferdinandy5, Tamás Csont4, Csaba Csonka4, Jacques Van Rooyen1.
Abstract
BACKGROUND: Red palm oil (RPO) and rooibos have been shown to exhibit cardioprotective properties. RPO is rich in essential fatty acids and fat soluble antioxidants while rooibos contains polyphenolic compounds with a unique composition of flavonoids. They exert their biological effects in different cellular compartments. Therefore the combination of these two natural food compounds has the potential to enhance the spectrum of available dietary antioxidants in different cellular compartments, which could result in an enhanced protection against certain pathological conditions such as inflammation.Entities:
Year: 2014 PMID: 25598708 PMCID: PMC4297406 DOI: 10.1186/s12950-014-0041-4
Source DB: PubMed Journal: J Inflamm (Lond) ISSN: 1476-9255 Impact factor: 4.981
Composition of Carotino RPO premium consumed by the rats
|
|
|
|
|---|---|---|
| Fatty acids% | 0.1 max | 0.058 |
| Moisture and impurities,% | 0.1 max | 0.03 |
| Iodine Value | 48-53 | 51.2 |
| Slip melting point, c | 33-37 | 36.4 |
| Carotenes, ppm | 400 min | 420 |
| Tocopherols and Tocotrienols, ppm | 400 min | 860 |
| Nutritional information | ||
| Amt/serving | Qty per 14 g | Qty per 100 g |
| Energy | 518 kJ | 3700 kJ |
| Protein | 0.0 g | 0.0 g |
| Fat, total | 14 g | 100 g |
| saturated | 7.0 g | 50.0 g |
| Trans | 0.0 g | 0.0 g |
| polyunsaturated | 1.5 g | 11.0 g |
| monounsaturated | 5.5 g | 39.0 g |
| Cholesterol | 0.0 g | 0.0 g |
| Carbohydrates | 0.0 g | 0.0 g |
| sugars | 0.0 g | 0.0 g |
| Sodium | 0.0 g | 0.0 mg |
| Carotenes as Vitamin A activity | 640 ug | 4600 ug |
| Vitamin E | 2.5 mg | 18.0 mg |
| Tocopherols | 1.7 mg | 12.0 mg |
| Tocotrienols | 4.8 mg | 34.0 mg |
Certificate of analysis prescribed by Carotino 2010.
www.carotino.com.
Study design illustrating the experimental groups and study protocol
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| Feeding time | 28 days | 28 days | 28 days | 28 days | 28 days | 28 days | 28 days | 28 days |
| Treatment | PBS | PBS | PBS | PBS | LPS | LPS | LPS | LPS |
| *Heart excision and perfusion protocol | *Heart excision and perfusion protocol | |||||||
RB: rooibos.
RPO: red palm oil.
LPS: liposaccharide.
Treatment: 0.5 mg/kg LPS was injected intraperitoneally to induce inflammation while 0.1 ml PBS was injected as a vehicle in control groups 18 hours prior to sacrificing.
*Hearts were excised and perfused for 20 minutes in a Langendorrf mode, baseline heart function was recorded at 20 minutes after which hearts were freeze clamped for cytokine analysis.
Figure 1Effects of inflammation, rooibos and RPO on plasma IL-1β (a), IL-6 (b), and IL-10 (c) levels. Results are means ± SEM, n = 4-8/group. #p < 0.05: LPS control vs NO-LPS control, *p < 0.05: treated vs. corresponding control. RPO: Red palm oil.
Figure 2Effects of inflammation, rooibos and RPO on myocardial IL-1β (a), IL-6 (b), and IL-10 (c) levels. Results are means ± SEM, n = 5-7/group. #p < 0.05: LPS control vs NO-LPS control, *p < 0.05: treated vs. corresponding control. RPO: Red palm oil.
Effects of inflammation, rooibos and RPO on baseline cardiac functional parameters in the NO-LPS group and the LPS group
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| CF (ml/min) | 13.92 ± 1.00 | 13.84 ± 1.00 | 14.6 ± 1.00 | 15.2 ± 1.00 | 14.30 ± 0.60 | 13.70 ± 0.70 | 14.60 ± 0.70 | 15.10 ± 0.20 |
| HR bpm (1/min) | 294.33 ± 6.00 | 277.87 ± 13.00 | 279.69 ± 15.00 | 296.313 ± 8.00 | 293.14 ± 14.00 | 302.39 ± 12.00 | 296.86 ± 10.00 | 300.00 ± 13.00 |
| LVDevP (mmHg) | 92.804 ± 6.00 | 86.40 ± 6.00 | 86.47 ± 5.00 | 97.00 ± 3.00 | 106.25 ± 4.30 | 89.60 ± 2.40 | 95.500 ± 4.50 | 100.90 ± 4.410 |
| RPP (Bpm*mmHg) | 27593.83 ± 1814.00 | 23706.98 ± 660.00 | 24383.99 ± 2503.00 | 28319.93 ± 764.00 | 30133.51 ± 1394.00 | 24805.68 ± 1366.00 | 24701.52 ± 1551.00 | 26176.72 ± 1212.00 |
| dp/dt (+) (mmHg/sec) | 2822.951 ± 149.00 | 2829.72 ± 84.00 | 2661.67 ± 198.00 | 2664.75 ± 112.00 | 3065.48 ± 103.00 | 2888.66 ± 129.00 | 2885.71 ± 80.00 | 2814.45 ± 113.00 |
| dp/dt (−) (mmHg/sec) | 1933.91 ± 70.00 | 1906.73 ± 82.00 | 1918.94 ± 103.00 | 1996.27 ± 94.00 | 2140.53 ± 90.00 | 1969.86 ± 69.00 | 2024.86 ± 120.00 | 1952.45 ± 51.00 |
| EDLVP (mmHg) | 10.256 ± 0.92 | 13.424 ± 2.20 | 11.558 ± 0.72 | 12.29 ± 1.34 | 13.74 ± 2.36 | 12.93 ± 1.33 | 12.22 ± 2.24 | 11.78 ± 1.16 |
| HW (g) | 1.17 ± 0.09 | 1.16 ± 0.05 | 1.11 ± 0.041 | 1.09 ± 0.03 | 1.32 ± 1.0 | 1.11 ± 0.0 | 2.82 ± 1.4 | 1.28 ± 0.1 |
| BW (g) | 333.70 ± 4.53 | 343.90 ± 10.02 | 346.60 ± 6.80 | 348.20 ± 3.40 | 350.20 ± 7.5 | 352.40 ± 7.4 | 334.20 ± 8.8 | 340.40 ± 90 |
No significant differences were observed in baseline cardiac function between the groups. Results are expressed as SEM, n = 5-7. CF- Coronary flow, HR- Heart rate, LVDevP- Left ventricular developed pressure, RPP- Rate pressure product, dp/dt (+) - maximum of LVDevP derivative, dp/dt (-) - minimum of LVDevP derivative, EDLVP- End diastolic left ventricular pressure, HW- Heart weight, BW- Body weight.